Key catalysts to watch: Phase 2 axatilimab data in IPF and cGVHD (both 4Q26), revumenib proof-of-principle trial initiation in MF (4Q26), and IND filings for SNDX-4321 (YE 2026) and SNDX-62122 (2027). The pipeline expansion into NSCLC and MF opens new blockbuster opportunities but adds clinical and regulatory risk. Monitor enrollment timelines and early safety/efficacy signals from the MF proof-of-principle trial.
Price Chart
Executive Summary
Syndax held an R&D event unveiling two new pipeline assets: SNDX-4321, a mutant-selective allosteric EGFR inhibitor for NSCLC, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis. The company also highlighted upcoming Phase 2 data readouts for axatilimab in IPF (4Q26) and axatilimab + ruxolitinib in cGVHD (4Q26), and reiterated that Revuforj and Niktimvo are annualizing at ~$200M combined as of 1Q26. No financial results were reported; the filing is a strategic pipeline update.
Key Facts
- Unveiled SNDX-4321, a mutant-selective allosteric EGFR inhibitor for NSCLC; IND submission expected by YE 2026, Phase 1 in 2027.
- Unveiled SNDX-62122, a next-generation menin inhibitor for myelofibrosis; IND and Phase 1 expected in 2027.
- Phase 1/2 proof-of-principle trial of revumenib in myelofibrosis expected to initiate in 4Q26 with initial data in 2H27.
- Phase 2 MAXPIRe trial of axatilimab in IPF on track for topline data in 4Q26.
- Phase 2 axatilimab + ruxolitinib data in cGVHD expected 4Q26.
- Revuforj and Niktimvo combined annualizing at ~$200M as of 1Q26.
- Company expects to have at least 4 innovative assets in the clinic by 2027.
- SNDX-4321 is an externally developed molecule with exclusive worldwide license; SNDX-62122 is internally developed and wholly owned.
Financial Impact
No financial results reported. Revuforj and Niktimvo combined annualizing at ~$200M as of 1Q26. Company states it is fully funded to advance late-stage trials and pipeline assets.
Risk Factors
- All pipeline assets are preclinical or early-stage; clinical failure risk is high.
- SNDX-4321 faces competition from multiple 4th-gen EGFR inhibitors and bispecific antibodies in development.
- Revumenib MF trial is proof-of-principle; clinical translation of preclinical data is uncertain.
- No financial guidance or revenue figures beyond the ~$200M annualization rate were provided.
- Reliance on partnerships (MPN-RC consortium, Incyte-led trials) introduces execution dependency.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-302608 |
| Document: sndx-20260714.htm | 0001193125-26-302608 |
| Document: sndx-ex99_1.htm | 0001193125-26-302608 |
| Document: 0001193125-26-302608-index-headers.html | 0001193125-26-302608 |
| Document: 0001193125-26-302608-index.html | 0001193125-26-302608 |
| Document: 0001193125-26-302608.txt | 0001193125-26-302608 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 14, 2026 11w ago | 8-K | $24.13 $20.29 | ▼ −15.91% | ▼ −18.41% | $17.60 (−27.06%) |
Jul 1, 2026 13w ago | Press Release | $21.82 $19.48 | ▼ −10.72% | ▼ −10.31% | $17.60 (−19.34%) |
Jun 11, 2026 16w ago | Press Release | $17.91 $24.84 | ▲ +38.69% | ▲ +36.80% | $17.60 (−1.73%) |
Jun 10, 2026 16w ago | 8-K | $17.91 $24.84 | ▲ +38.69% | ▲ +36.80% | $17.60 (−1.73%) |
Jun 4, 2026 17w ago | Press Release | $17.34 $22.08 | ▲ +27.34% | ▲ +25.47% | $17.60 (+1.50%) |
Jun 4, 2026 17w ago | DEFA14A | $18.02 $21.82 | ▲ +21.09% | ▲ +22.46% | $17.60 (−2.33%) |
Jun 4, 2026 17w ago | 8-K | $18.02 $21.82 | ▲ +21.09% | ▲ +22.46% | $17.60 (−2.33%) |
Apr 30, 2026 22w ago | DEFA14A | $19.11 $18.85 | ▼ −1.36% | ▼ −6.64% | $17.60 (−7.90%) |
Apr 24, 2026 23w ago | Press Release | $21.39 $19.77 | ▼ −7.57% | ▼ −11.60% | $17.60 (−17.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access